Last updated on February 2016

Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment


Brief description of study

To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or renal impairment

Clinical Study Identifier: NCT02696642

Contact Investigators or Research Sites near you

Start Over